Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease

Background and Objectives: Real-world evidence of apixaban treatment in patients with chronic kidney disease remains scarce. This study aimed to compare the relative risk of stroke or systemic embolism (SE) and major bleeding between apixaban and warfarin in atrial fibrillation (AF) patients with di...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Chung-Ming, Li, Lung-Chih, Lee, Yueh-Ting, Wang, Shih-Wei, Hsu, Chien-Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558356/
https://www.ncbi.nlm.nih.gov/pubmed/34733897
http://dx.doi.org/10.3389/fcvm.2021.752468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558356/
https://www.ncbi.nlm.nih.gov/pubmed/34733897
http://dx.doi.org/10.3389/fcvm.2021.752468

Ejemplares similares